or
Continue with FacebookLooking to list your PhD opportunities? Log in here.
This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunities
Prof Andrew Sutherland
No more applications being accepted
Competition Funded PhD Project (European/UK Students Only)
About the Project
Medical Research Scotland
PhD Studentship Awards
This project is one of six four-year PhD Studentships funded by Medical Research Scotland (http://www.medicalresearchscotland.org.uk) to be delivered jointly by the named University and Company. The Studentships will provide the first-class academic and commercial training needed to equip the successful student for a science career in an increasingly competitive market.
New Metal Catalysed Methods for the Efficient, Non-toxic Generation of PET and SPECT Tracers: Molecular Imaging of Neurological Disease - delivered by the University of Glasgow and GE Healthcare (http://www3.gehealthcare.co.uk)
Academic Supervisors: Dr Andrew Sutherland & Dr Sally Pimlott; Company Supervisor: Dr Sajinder Luthra
Radionuclide molecular imaging is increasingly used for the early diagnosis of both neurological diseases and cancer. However, the widespread application of this technology is being limited due to current methods of generating the imaging agents which can involve unstable, highly toxic precursors. In collaboration with GE Healthcare, this PhD programme of research will investigate new transiton metal-catalysed chemical reactions that will allow simple, easy access to PET and SPECT tracers from readily available, non-toxic starting materials. In particular, the project will investigate the use of nickel catalysts for the incorporation of radiohalogens into aromatic compounds, structural motifs that are found extensively in molecular tracers. On development of each new reaction, the versatility of this process will be demonstrated by the preparation of molecular tracers used in the imaging of cancer and neurological disorders, particularly Alzheimer's disease. Discovery and successful development of these new chemical transformations for the non-toxic and facile preparation of PET and SPECT imaging agents will accelerate the application of this technology across the NHS and the pharmaceutical/life sciences industries.
PhD Studentship Awards
This project is one of six four-year PhD Studentships funded by Medical Research Scotland (http://www.medicalresearchscotland.org.uk) to be delivered jointly by the named University and Company. The Studentships will provide the first-class academic and commercial training needed to equip the successful student for a science career in an increasingly competitive market.
New Metal Catalysed Methods for the Efficient, Non-toxic Generation of PET and SPECT Tracers: Molecular Imaging of Neurological Disease - delivered by the University of Glasgow and GE Healthcare (http://www3.gehealthcare.co.uk)
Academic Supervisors: Dr Andrew Sutherland & Dr Sally Pimlott; Company Supervisor: Dr Sajinder Luthra
Radionuclide molecular imaging is increasingly used for the early diagnosis of both neurological diseases and cancer. However, the widespread application of this technology is being limited due to current methods of generating the imaging agents which can involve unstable, highly toxic precursors. In collaboration with GE Healthcare, this PhD programme of research will investigate new transiton metal-catalysed chemical reactions that will allow simple, easy access to PET and SPECT tracers from readily available, non-toxic starting materials. In particular, the project will investigate the use of nickel catalysts for the incorporation of radiohalogens into aromatic compounds, structural motifs that are found extensively in molecular tracers. On development of each new reaction, the versatility of this process will be demonstrated by the preparation of molecular tracers used in the imaging of cancer and neurological disorders, particularly Alzheimer's disease. Discovery and successful development of these new chemical transformations for the non-toxic and facile preparation of PET and SPECT imaging agents will accelerate the application of this technology across the NHS and the pharmaceutical/life sciences industries.
Funding Notes
The PhD Studentship provides: an annual tax-free stipend of £16,000, increasing to £16,500 over the four years; tuition fees at UK/EU rates only; and consumables. Please note international fees are not covered.
Applicants should hold (or expect to be awarded) a first class or upper-second class Masters degree (MSci, MChem, MSc, MRes) or equivalent in Chemistry and have a background that includes synthetic chemistry.
Applications should include a full CV, with details of all University course grades to date, contact details of at least two academic referees and a cover letter outlining your suitability for the PhD position.
Applicants should hold (or expect to be awarded) a first class or upper-second class Masters degree (MSci, MChem, MSc, MRes) or equivalent in Chemistry and have a background that includes synthetic chemistry.
Applications should include a full CV, with details of all University course grades to date, contact details of at least two academic referees and a cover letter outlining your suitability for the PhD position.
References
1. A. A. Cant, R. Bhalla, S. L. Pimlott and A. Sutherland, Nickel-Catalysed Aromatic Finkelstein Reaction of Aryl and Heteroaryl Bromides, Chem. Commun., 2012, 48, 3993-3995.
2. S. L. Pimlott and A. Sutherland, Molecular Tracers for the PET and SPECT Imaging of Disease, Chem. Soc. Rev., 2011, 40, 149-162.
3. http://www.chem.gla.ac.uk/staff/andrews/
2. S. L. Pimlott and A. Sutherland, Molecular Tracers for the PET and SPECT Imaging of Disease, Chem. Soc. Rev., 2011, 40, 149-162.
3. http://www.chem.gla.ac.uk/staff/andrews/
Find a scholarship to fund your dream Masters
Sign in to view and filter all scholarship opportunities
or
Continue with Facebook